Korsana Biosciences, Inc. (KRSA) reports a proposed sale by director Michael Higgins of 1,107 common shares, with an aggregate market value of $35,424.00 and an approximate sale date of October 22, 2026, through Morgan Stanley Smith Barney LLC. The shares were acquired upon vesting of restricted stock from November 30, 2023, through June 1, 2026. The notice also lists prior sales by Higgins of 1,001 shares for $33,033.00 on September 18, 2026, and 235 shares for $7,599.71 on September 17, 2026.
Korsana Biosciences, Inc.'s ownership amendment reports that J. Wood Capital Advisors LLC held of record 25,974 shares of common stock as of September 30, 2026; Jason Wood, its managing member, may be deemed to share beneficial ownership. Each reporting person reported 0.1% of the class and shared voting and dispositive power over 25,974 shares. The ownership calculation uses 45,541,425 shares outstanding as of September 8, 2026.
Korsana Biosciences, Inc. (KRSA) seeks approval to redomesticate from Massachusetts to the Cayman Islands at a November 13, 2026 special meeting. Both the domestication and continuation/Cayman Articles proposals must pass. With a quorum, Proposal No. 1 requires the affirmative vote of not less than two-thirds of all shares entitled to vote; Proposal No. 2 requires not less than two-thirds of votes properly cast. Abstentions and uncast shares count against Proposal No. 1; Proposal No. 3 would allow adjournment to seek more proxies.
At the August 26, 2026 annual meeting, approximately 61.8% of votes cast favored redomestication, representing approximately 44.8% of shares entitled to vote. As of October 7, 2026, 45,541,358 common shares were outstanding and entitled to vote. If approved and effected, each common share automatically converts into one Cayman ordinary share. Korsana would remain the same legal entity, with no change to its business, management, assets or liabilities other than transaction costs; its Nasdaq Capital Market listing under KRSA would continue.
If both proposals pass and required filings are made, Korsana anticipates effectiveness as soon as practicable after the meeting, but the Board may delay or abandon the change. Cayman law would govern shareholder rights, including three-year staggered board terms and an exclusive Cayman forum for specified disputes. The Board unanimously recommends all three proposals.
Korsana Biosciences, Inc. was the subject of an amended beneficial-ownership report by FMR LLC and Abigail P. Johnson, each reporting beneficial ownership of 3,144,797 shares of common stock, or 6.9%, as of September 30, 2026. FMR LLC reported sole voting and dispositive power over 3,144,797 shares; Abigail P. Johnson reported zero sole voting power and sole dispositive power over 3,144,797 shares. Both reported zero shared voting and dispositive power. Other persons were described as having rights to dividends or sale proceeds, but no other person's interest exceeded 5% of the class.
Korsana Biosciences, Inc. (KRSA) is asking shareholders to approve moving its legal domicile from Massachusetts to the Cayman Islands at a special meeting scheduled for November 13, 2026. The proposal requires approval of both the domestication measure, by at least two-thirds of all shares entitled to vote, and the continuation and Cayman Articles measure, by at least two-thirds of votes properly cast. If either fails, the change will not take effect.
If approved and required filings are made, Korsana would continue as the same legal entity, and each outstanding common share would automatically convert into one Cayman ordinary share without holder action. The company says its business, management, offices, assets and liabilities would remain unchanged, and its shares would continue on the Nasdaq Capital Market under KRSA. Shareholder rights would shift to Cayman law, including a board divided into three classes with staggered three-year terms rather than annual director elections. The board may delay or abandon the transaction before it takes effect if it determines that doing so is in the company’s and shareholders’ best interests.
Korsana Biosciences, Inc. (KRSA) director Errol B. De Souza reported a proposed sale of 4,903 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $171,555.97 and an approximate sale date of September 23, 2026. The shares were acquired upon vesting of restricted stock between October 1, 2024, and July 16, 2026.
Korsana Biosciences, Inc. (KRSA) director Errol B. De Souza has filed a Form 144 notice to sell 100 shares of common stock through Morgan Stanley Smith Barney, with an indicated aggregate value of $3,499.00 on Nasdaq. The shares to be sold were acquired upon the vesting of restricted stock during the period from September 1, 2024 through October 1, 2024. Over the prior three months, De Souza reported sales of 2,139 shares of common stock for $74,843.61.
Korsana Biosciences, Inc. (CYCN) has a new large shareholder group led by General Atlantic investment entities, which together report beneficial ownership of 3,201,131 shares of common stock, representing 6.8% of the company. The position is held through General Atlantic (KB), L.P., which owns 1,366,242 shares of common stock and a Pre-Funded Warrant to purchase an additional 1,834,889 shares.
The 6.8% ownership is calculated against an aggregate base of 47,376,314 shares, including shares issuable upon warrant exercise. Multiple General Atlantic partnerships and co-investment vehicles may be deemed to share voting and dispositive power, and warrant exercises are limited by a 9.99% beneficial-ownership blocker.
Korsana Biosciences, Inc. (CYCN) director Errol B. De Souza has filed a notice of proposed sale under Rule 144 for 2,139 shares of common stock of the company, to be handled through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares relate to restricted stock that vested between November 30, 2023 and September 1, 2024, and the filing lists an approximate aggregate market value of $74,843.61 for the securities covered by this notice as of September 18, 2026.
Korsana Biosciences, Inc. (CYCN) is reported to have a significant shareholder, Wellington Biomedical Innovation Master Investors (Cayman) II, L.P., which has filed as a passive holder on a Schedule 13G. The fund reports beneficial ownership of 2,775,788 shares of common stock, representing 6.10% of the class.
The filing states the holder has shared power to vote and dispose of all 2,775,788 shares, with no sole voting or dispositive power. This positions the Wellington-affiliated fund as a notable institutional investor in Korsana Biosciences without indicating any change of control intent.